BRIEF-Lilly says phase 3 breast cancer study meets primary endpoint
March 20, 2017 at 07:03 AM EDT
* Lilly announces phase 3 monarch 2 breast cancer study of abemaciclib met primary endpoint of progression-free survival
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.